Bremelanotide (PT-141) Troches Compounded

Bremelanotide (PT-141) is an FDA approved treatment for Hypoactive Sexual Desire (HSDD) in women.

Pronunciation:

(BRE me LAN oh tide)

Other Names:

Brand Names (U.S.): Vyleesi

Drug Class:

Melanocortin Receptor Agonist

Mechanism of Action:

The current mechanism of action of bremelanotide is unknown.

Drug Interactions:

Indomethacin: Bremelanotide may decrease the serum concentration of Indomethacin. Risk C: Monitor therapy

Naltrexone: Bremelanotide may decrease the serum concentration of Naltrexone. Risk X: Avoid combination

Adverse Effects:

Common Side Effects:

• Nausea
• Flushing
• Injection site irritation
• Vomiting
• Stuffy nose
• Cough
• Tingling
• Fatigue
• Weakness

Tell your doctor if you begin to have any of these symptoms following gabapentin administration:

• Severe headache
• Severe dizziness
• Passing out
• Vision changes
• Slow heartbeat
• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Administration:

Use this drug as ordered by your prescriber.

Dosing:

Contact your healthcare provider for specific dosing instructions.

Pregnancy:

Outcome information following maternal use of bremelanotide during pregnancy is limited. Contact your prescriber and discontinue if pregnancy is suspected.

Breastfeeding:

It is not known if bremelanotide is present in breast milk.

References:

1. Bremelanotide [Lexi-Drugs]. Lexi-Comp. Wolters Kluwer Health, Inc. https://fco.factsandcomparisons.com